Showing posts with label medicine. Show all posts
Showing posts with label medicine. Show all posts

Tuesday, December 15, 2020

Researchers Find New Method to Measure Cognitive Impairment, Dementia

This article, " Health-Deficit Accumulation Affects Risk for Mild Cognitive Impairment, Dementia," was originally published in NeurologyLive.

Using a frailty index score could enable clinicians to identify patients at risk for cognitive dysfunction, making it an important marker for prognostic value.

Newly published data suggests health-deficit accumulation, specifically among older Americans, affects the likelihood of progressive cognitive impairment, as well as the likelihood of cognitive improvement independent of the APOE ε4 allele.

Lead author David D. Ward, PhD, postdoctoral fellow, geriatric medicine research, Centre for Health Care of the Elderly, Nova Scotia Healthy Authority, and colleagues calculated a frailty index score using the deficit-accumulation approach in participants aged 50 years and older from the National Alzheimer’s Coordinating Center (NACC).

Among those not cognitively impaired (NCI; n = 9773), each 0.1 increment increase in score were associated with a higher risk of developing mild cognitive impairment (MCI) and a higher risk of developing dementia.

In total, there were 14,490 participants in the study with a mean age of 72.2 years. In the MCI subsample (n = 4717) at baseline, there was a higher degree of frailty that was associated with a lower probability of being reclassified as NCI from MCI, a higher risk of returning to MCI in those who were reclassified as NCI, and a higher risk of progressing to dementia.

"We conclude that frailty is a key risk factor for age-related cognitive dysfunction and dementia, representing both a target for interventions aimed at the prevention of age-related cognitive impairment and possible prognostic marker among those who have MCI,” the authors wrote.

The score is a health-state measure, incorporating information from multiple physiological systems, and closely reflects an individual’s risk for adverse health events and mortality independently of chronological age. A higher frailty index score indicated accumulation of more age-related health deficits while approximating biological age.

The researchers aimed to detail the dynamic nature of cognitive functioning by calculating the likelihood of transitions between cognitive states in both directions over a 12-month period. Decline of cognitive function was considered forward transition, whereas improvement of cognitive functioning was defined as backwards transition.

The investigators also assessed whether frailty index score and APOE ε4 allele carrier status exerted independent or interactive effects on cognitive-state transition probabilities.

They found no statistically significant interactions between these variables for any transition in the NCI subsample. However, in the MCI subsample, the association of the frailty index score and the risk of progressing to dementia was significantly weaker in those carrying an APOE ε4 allele than in non-carriers (interaction hazard risk [HR], 0.88; 95% CI, 0.80–0.97).

There were no meaningful differences in these associations when participants whose race was other than white were removed from the analytical sample. Notably, associations of the frailty index score with transition probabilities did not differ significantly between men and women.

Over 12 months, NCI subsample participants maintained their prior state 43,086 times (90.6%) and transitioned between states 4491 times (9.4%), 3086 (68.7%) of which were transitions between cognitive states, with 1405 (31.3%) transitions to death. Of the cognitive-state transitions in the NCI subsample, 80.9% were forward transitions, and 19.1% were backward transitions. In the MCI subsample, 70.5% were forward compared to 29.5% who experienced backwards transition.

"This work supports an emerging conceptualization of late-onset dementia as a complex outcome of aging that often is intimately related to an individual’s general health, as well as genetic risk factors,” the authors wrote.

Friday, December 11, 2020

Particulate Matter Increases Future Risk of Alzheimer Disease

Progressive brain atrophy known to be predictive of Alzheimer disease (AD) is linked to late-life exposure to particulate matter with aerodynamic diameters <2.5-μm (PM2.5), according to new research.

Longitudinal analyses showed that for each interquartile range (IQR) increase (IQR, 2.82- μg/m3) of PM2.5, the associated risk of developing AD increased by 24% (hazard ratio [HR], 1.24; 95% CI, 1.14–1.34) over a 5-year period, as assessed by increased AD pattern similarity (AD-PS) scores. This association remained within levels of PM2.5 below US regulatory standards (<12-μg/m3).

Principal author Diana Younan, PhD, research associate, University of Southern California, stated in a related release that the “findings have important public health implications because not only did we find brain shrinkage in women exposed to the highest levels of PM2.5 pollution but we also found it in women exposed to levels lower than those that the EPA considers safe.”

Younan and colleagues investigated data from 1365 women free of dementia with a mean age of 77.9 years (standard deviation [SD], 2.7) that participated in the WHIMS Magnetic Resonance Imaging (WHIMS MRI) study.

MRI data at baseline and after 5 years was investigated. AD-PS scores—which have been shown to be associated with known risk factors of AD and poor cognitive function—were developed by a supervised machine learning algorithm by comparison of MRI data from the AD Neuroimaging Initiative of gray matter atrophy in areas vulnerable to AD such as the amygdala, hippocampus, thalamus, midbrain, parahippocampal gyrus, and inferior temporal lobe areas.

In longitudinal analysis, IQR-increments were significantly associated with a 0.031 (β = 0.031; 95% CI, 0.017–0.046) increase in AD-PS score.

In fully adjusted models the association was 0.026 (95% CI, 0.009–0.043), which correlates to the 24% increase of AD risk. This association remained after adjusting for socio-demographics, lifestyle, and clinical characteristics including cerebrovascular factors such as white matter lesion volume and stroke, challenging previous studies that have proposed a cerebrovascular mechanism of PM2.5 damage leading to brain atrophy.

Instead, Younan and colleagues favor the theorized mechanism that PM2.5 directly contributes to the neurodegenerative process of dementia via a neurotoxic effect on brain structure.

Sensitivity analyses confirmed the positive association between PM2.5 and AD-PS score after adjusting for baseline AD-PS scores. No association was seen between PM2.5 and baseline AD-PS score in cross sectional analyses (β = –0.004; 95% CI, –0.019 to 0.011).

Previous analyses of WHIMS MRI include region-of-interest analyses that showed residence in areas with higher PM2.5 was associated with smaller total brain and white matter volumes, and that residing in places with >12-μg/m3 concentrations of PM2.5 increased the risk of global cognitive decline by 81% and all-cause dementia by 92%.

Younan and colleagues call for future studies “to fully investigate whether the neurodegenerative effects of late-life exposures to airborne particles may be contributed by or independent of cerebrovascular damage before or during late life...to replicate these results and to thoroughly explore other measures of cerebrovascular damage that may not be captured by white matter lesions and were not explored in our study (e.g., microbleeds; lacunar infarcts).”


Thursday, March 10, 2016

7 Best FDA Approved Health Apps — An Update

 

health-care-of-the-future-connected-and-mobile

As the mobile health industry continues to rapidly expand with no signs of slowing down, FDA regulation of health apps has evolved too.

Today, there are more than 100,000 mobile health apps on the market for Apple and android devices, with mobile health revenues projected to jump to $26 billion by 2017, according to Mobile Health Economics.

In February 2015, the FDA announced plans to review mobile medical apps that interpret data and act like medical devices. (We include examples of companies the FDA warned about this at the end of this post.)

The agency is basically making a call on the safety and effectiveness of certain apps. “Some mobile apps carry minimal risks to consumer or patients, but others can carry significant risks if they do not operate correctly. The FDA’s tailored policy protects patients while encouraging innovation,” said Jeffrey Shuren, M.D., J.D., Director of the FDA’s Center for Devices and Radiological Health, in a statement.

The agency does not intend to regulate apps that track a person’s daily steps, enable patients to refill prescriptions or search medical references. Nor will they oversee the mobile devices, such as iPhones and tablets, which can run medical apps.

It’s important to know which apps are worth your precious time and money. Therefore, PYP updated our popular 2013 list of the best FDA approved health apps and devices:


AirStrip ONEAirStrip ONE evolved from a diagnostic aid that delivers patient data from medical devices, electronic medical records and patient monitors to clinicians – to a platform that enables mobile interoperability. AirStrip Technologies’ platform intends to connect clinicians with patient data and with other providers to share data and promote care collaboration.


AliveCor
AliveCor Mobile ECG turns your smartphone into an electrocardiogram by snapping on the back of an iPhone. To take cardiac measurements, a person presses the device against the skin over the heart. A new feature allows people to keep a digital journal and track their symptoms, activity and diet.


Diabetes Manager
This device captures blood-glucose information and transmits it in real-time. WellDoc’s system offers a personalized coach to help patients manage their medication and treatment. WellDoc now calls its device BlueStar, and offers a commercial model that also engages a healthcare team in the management of type 2 diabetes.


iExaminerWelch Allyn designed its iExaminer app and ophthalmoscope to help with detection of conditions like glaucoma or retinopathy of prematurity. The ophthalmoscope connects to an iPhone 4 or 4S and allows providers to store the pictures to a patient file or email and print them.


Mobile MIM
The first medical app ever offered through iTunes, MIM Software designed the Mobile MIM to share images from radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. The company intends this health app to enhance physician access to image scans to help them consult with peers on challenging cases, reduce image distribution delays and share images with referring physicians, partner institutions and patients.


ResolutionMDResolutionMD diagnostic medical imaging software from Calgary Scientific allows providers to securely access patient images and reports across a single practice or large enterprise healthcare system. Providers can securely review and collaborate from web and mobile devices without downloading any sensitive data.


Triton iPad App
In March 2015, the FDA cleared the Triton iPad App for estimating blood loss during surgery. This app takes a photo of a blood collection container using an iPad camera, and then analyzes it in the cloud. In 2012, the FDA cleared the Pixel app, also from Gauss Surgical. Pixel estimates blood loss during surgery by scanning blood filled sponges in an operating room.

So there you have our recommendations for the most useful, not to mention coolest, FDA-approved health apps on the market for physicians.

Apps the FDA Snagged in the Past

In 2013, the FDA sent an official warning letter to Biosense Technologies Private Limited about their uChek Urine Analyzer. Although the app connects a smartphone to FDA cleared reagent strips, because it allows a phone to analyze the results, it’s considered a medical device.

The FDA might also block importation of a mobile device if a company doesn’t first secure 501(k) clearance. This was the case for EPI Mobile Health Solutions of Singapore, whose Bluetooth-enabled mobile ECG device the FDA prevented from entering the U.S. for nearly one year.


Medical Office Supplies

15% Off All Products!